Abstract 752
Background
The neutrophil–lymphocyte ratio (NLR) is recognized as a prognostic marker in many cancers, including metastatic castration-resistant prostate cancer (mCRPC). In this study, we perform a retrospective analysis of the pivotal COU302 study of abiraterone acetate (AA) as first line therapy for men mCRPC.
Methods
The COU302 study randomized men with minimally symptomatic mCRPC to 1000mg AA once daily plus 5mg prednisone (AA + P) twice daily or placebo plus 5mg prednisone (P) twice daily. We utilized Kaplan–Meier survival and cox proportional hazard analyses to assess the effect of baseline NLR on response to AA + P versus P. Adjustment co-variates were selected from a recently reported analysis of the PREVAIL study of enzalutamide in men with mCRPC. Based on this analysis, we selected a NLR cut-off value of 2.5. Outcomes assessed included the co-primary endpoints from the COU302 study overall survival (OS) , radiographic progression free-survival (RPFS) and PSA progression-free survival (PFS).
Results
Among the 1088 patients in the COU302 study, baseline NLR values showed significant differences according to baseline albumin below median (3.16 vs 2.92, p = 0.011), but no other baseline covariates. Mean NLR significantly increased following treatment initiation and at the end of study compared to baseline. Among patients with a baseline NLR ≥2.5, there was similar OS in AA + P and P treatment arms (p = 0.26), which was confirmed on adjusted cox proportional hazards (AA +P HR 0.95, p = 0.65). AA + P showed a significant OS benefit versus P (p = 0.0011) in men with baseline NLR <2.5, with an adjusted HR of 0.723(p = 0.012). For RPFS, benefits for AA + P were seen in men with NLR <2.5 or ≥ 2.5, with the magnitude of benefit greater in men with NLR <2.5. In the AA + P arm, men with baseline NLR <2.5 had significantly better PSA PFS compared to baseline NLR ≥2.5 (p = 0.03); no significant differences were seen in men in the placebo arm.
Conclusions
In the COU302 study, we observed that patients with a screening NLR<2.5 had a significant benefit to AA + P compared to P, whereas for patients with a screening NLR ≥2.5, this benefit was less evident. Increases in the NLR value from baseline could not be used to predict response to AA.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
V. Fradet: Speaker: Abbvie, Bayer, Ferring, Janssen, Sanofi; Consultant: Amgen, AstraZeneca, Astellas, Bayer, Ferring, Janssen, Sanofi; Adviser: Amgen, Astellas, Bayer, Ferring, Janssen, Sanofi; Research grant: Amgen, AstraZeneca, Astellas, Janssen, Sanofi; Clinical trial: AstraZeneca, Bayer, Janssen; Meeting sponsor: Bayer, Janssen, Lilly; Educational grant: Janssen. P. Toren: Scientific study or trial: Innocrin Pharma, Roche; Consultant, Advisor: Sanofi Canada, Ferring, Astellas, Abbvie. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract